New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link
…, TA Connors, DC Blakey, AB Mauger
Index: Dowell, Robert I.; Springer, Caroline J.; Davies, David H.; Hadley, Elizabeth M.; Burke, Philip J.; Boyle, F. Thomas; Melton, Roger G.; Connors, Thomas A.; Blakey, David C.; Mauger, Anthony B. Journal of Medicinal Chemistry, 1996 , vol. 39, # 5 p. 1100 - 1105
Full Text: HTML
Citation Number: 51
Abstract
Antibody-directed enzyme prodrug therapy (ADEPT) is a two-step approach for the treatment of cancer which seeks to generate a potent cytotoxic agent selectively at a tumor site. In this work described the cytotoxic agent is generated by the action of an enzyme CPG2 on a relatively nontoxic prodrug. The prodrug 1 currently on clinical trial is a benzamide and is cleaved by CPG2 to a benzoic acid mustard drug 1a. We have synthesized a series of ...
Related Articles:
[Schmidt; Florent; Monneret; Straub; Czech; Gerken; Bosslet Bioorganic and Medicinal Chemistry Letters, 1997 , vol. 7, # 8 p. 1071 - 1076]
[Schmidt; Florent; Monneret; Straub; Czech; Gerken; Bosslet Bioorganic and Medicinal Chemistry Letters, 1997 , vol. 7, # 8 p. 1071 - 1076]